(PharmaNewsWire.Com, July 23, 2020 ) This report provides a detailed overview of the major drivers, restraints, opportunities, and threat impacting the global top 10 bioprocess technology market along with the estimates and forecasts of the revenue and market share analysis.
Rapid growth in pharmaceutical and biotechnology industries, growth in the number of new drug launches, strong trend of R&D in life sciences research, increasing government support for pharmaceutical and biotechnology industries, and rising prevalence of chronic diseases are the key factors driving the growth of this market.
The global top 10 bioprocess technology market is segmented on the basis of type and region. On the basis of type, the market is segmented into cell culture, cell expansion, cell counting, flow cytometry, single-use bioprocessing, cell line development, virus filtration, biologics safety testing, pyrogen testing, and tangential flow filtration. In 2016, the cell culture segment is expected to account for the largest share of the global top 10 bioprocess technology market.
On the basis of region, the market is segmented into North America, Europe, Asia, and RoW. In 2016, the North American region is expected to account for the largest share of the global top 10 bioprocess technology market. This growth can be attributed to the increased R&D spending by pharmaceutical and biotechnology companies in this region.
The prominent players in the top 10 bioprocess technology market include GE Healthcare (U.S.), Merck Millipore (Germany), Thermo Fisher Scientific, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), Lonza Group AG (Switzerland), Sartorius Stedim Biotech S.A (France), Corning, Inc.(U.S.), Bio-Rad Laboratories (U.S.), and Charles River Laboratories (U.S.).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
